The specialty chemicals producer sweetened terms on a deal covering about $1 billion of loans after multiple delays over the past month.
The SK Capital-backed company has been under pressure because the debt matures in just over a year, making an extension or refinancing increasingly urgent.
Investor caution has been heightened by conflict in the Middle East and a broader slowdown in the chemicals sector, complicating efforts to complete the transaction.
How did Middle East tensions force a Swiss chemical firm to sweeten its $1 billion junk loan deal?
With Europe's chemical industry 'breaking,' can even specialty giants like Archroma afford to innovate?
Is Archroma's struggle a warning that the $2 trillion private credit boom is finally over?